Ardelyx (ARDX) announced the approval of a New Drug Application, NDA, by China’s Center for Drug Evaluation of the National Medical Products Administration for tenapanor to control serum phosphorus levels in dialysis patients with chronic kidney disease who have an inadequate response or are intolerant to phosphorus binders.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDX:
- Ardelyx (ARDX) Earnings Call: Strong Growth Amidst Challenges
- Ardelyx price target lowered to $13 from $15 at Raymond James
- Ardelyx Inc. Grapples with Trade Secret Risks Threatening Financial Stability
- Ardelyx Reports Strong 2024 Financial Performance
- Biotech Alert: Searches spiking for these stocks today